Bifidobacterium animalis subsp. lactis BL-11 Promotes Height Growth

in Children Aged 3-7 Years: A Self-controlled Cohort Study 2

- Qian Wang^{1#}, Yanan Yang^{2#}, Yin Xiao^{3#}, Ziyi Liu², Mingxi Li², Yue Yu¹, Nannan 4
- Wang¹, Junyan Li⁴, Xiaohui Li⁵, Chuanhui Xu⁶, Deyun Liu^{1*}, Chongming Wu^{2,7,8*} 5
- ¹ The Second Affiliated Hospital of Anhui Medical University, Hehui, Anhui, China. 7
- ² School of Chinese Materia Medica, Tianjin University of Traditional Chinese 8
- Medicine, Tianjin, China. 9
- ³ Anhui Medical University, Hehui, Anhui, China. 10
- ⁴ West China Second University Hospital, Sichuan University, Chengdu, Sichuan, 11
- 12 China.

1

3

6

- ⁵ New Century Women's and Children's Hospital, Beijing, China. 13
- 14 ⁶ Minerva Hospital for women and children, Chengdu, Sichuan, China.
- ⁷ Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, 15
- Tianjin, China 16

18

20

- ⁸ State Key Laboratory of Chinese Medicine Modernization 17
- # These authors contributed equally to this work. 19
- * Correspondence: 21
- 22 Deyun Liu, 13966699361@163.com; Chongming Wu, chomingwu@163.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Abstract Background: Short status of children has captured extensive attention since it reflects the health status of children and affects physical and psychological health throughout children's life. Compelling evidences have revealed that gut microbiota participates in the skeletal development directly or indirectly. Currently, the calcium agent and growth hormone-like drugs have provided potential opportunities to promote growth and development among children, yet limited trials existed with probiotic intake as a primary strategy. Objectives: Present cohort study was designed to evaluate the height-promoting effect of gut probiotic Bifidobacterium animalis subsp. lactis BL-11 among 3-7 years old children. Registered under ClinicalTrials.gov Identifier no. ChiCTR2400089723. **Methods**: This study was conducted with Chinese children aged 3 to 7 years (n = 124) who fall between the 3rd and 25th percentiles (P3-P25) for height, and whose annual growth rate in height is less than 5 cm. The Bifidobacterium animalis subsp. lactis BL-11 oiling agent were taken every day with total live bacteria \geq 30 billion. The height of each participant was measured and recorded before and after three-months Bifidobacterium animalis subsp. lactis BL-11 intervention. **Results**: Bifidobacterium animalis subsp. lactis BL-11 could strikingly promote the height growth of children, and shift the height percentile rage from P3-P10 to P10-P25. Importantly, this promoting effect has no specificity between age and sex. Comparatively, children with shorter height (P3-P10) were more sensitive to

Bifidobacterium animalis subsp. lactis BL-11.

- Conclusions: Administration of *Bifidobacterium animalis subsp. lactis* BL-11 as early 45
- as possible is in favor of the child's growth and development, which provided a 46
- strategy for pediatricians to address some plights that how to promote children's 47
- growth effectively and safely. 48
- Keywords: cohort study, gut microbiota, Bifidobacterium animalis subsp. lactis 50
- BL-11, growth-promoting 51

Introduction

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Recently, children suffering from growth delay have received social attentions, as the growth problem during early childhood higher the risk of long-term health, educational, and emotional problems for children [1,2]. According to World Health Organization (WHO) Global Database on Child Growth and Malnutrition, a child whose height is lower than the average age by more than two standard deviations is regarded as short stature [3]. Compelling evidences have proved that the short stature is closely related to the development of several disease, such as metabolic disease and cardiovascular diseases [4.5]. It is reported that an individual with short stature had about a 50% higher risk of coronary heart disease morbidity and mortality than tall ones [6]. Additionally, short stature can contribute to feelings of inferiority in children and negatively impact the development of a healthy personality. Hence, it is necessary to recognize the height problem in children as early as possible and to implement timely interventions. An intestinal probiotic is a type of bacteria that has been found to be non-harmful and to have beneficial effects on the host [7-9]. Various studies have demonstrated that administering Bifidobacterium spp. can enhance human immunity and improve disease resistance [10]. For instance, Bifidobacterium animalis subsp. Lactis BB-12® has been shown to reduce crying and fussing in infants diagnosed with infant colic Additionally, treatment with Lactobacillus acidophilus [11]. DDS-1 and Bifidobacterium animalis subsp. lactis UABla-12 alleviates the abdominal pain in patients with irritable bowel syndrome [12]. Bifidobacterium animalis subsp. lactis

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Bb12 may alleviate the unhealthy conditions of preterm infants [13]. Moreover, a meta-analysis demonstrated that probiotic Bifidobacterium animalis subsp. lactis CNCM I-3446 could exert positive effect on growth in infants born to mothers with human immunodeficiency virus (HIV) [14]. Thus, probiotic intervention appears to be a promising strategy for alleviating disease and enhancing human health, particularly for children and patients who are intolerant to conventional medications. However, the effectiveness of probiotics in promoting children's growth remains controversial and requires further clinical research to validate this hypothesis. To explore the potential efficacy of probiotics in promoting children's growth, we selected a strain of Bifidobacterium animalis subsp. lactis BL-11 which has shown to promote height in children with Prader-Willi Syndrome [15], and administered it to children aged 3-7 years for three months. The height were measured and recorded before and after intervention. As expected, there was a significant increase in height following the Bifidobacterium animalis subsp. lactis BL-11 intervention. This cohort study not only proved the role of probiotics in promoting children's growth, but also provided an effective intervention for addressing short stature in children. **Methods** Subjects and ethical approval Children of both sexes and aged 3-7 years who were recruited between Dec. 2023 and Sep. 2024. The study was conducted at the second affiliated hospital of anhui medical university. The enrollment and research plan were reviewed and approved by the institutional ethics committee of the second affiliated hospital of

96 anhui medical university (ethics number: SL-YX2023-172). Written informed consent

was obtained from each child's parents/guardians. This study complied with the code

of ethics of the World Medical Association (Declaration of Helsinki) and received

approval and registration in the Chinese Clinical Trial Registration Center with the 99

registration number ChiCTR2400089723.

Inclusion, exclusion, and withdrawal criteria

Inclusion Criteria 102

103 1. Aged 3-7 years.

97

98

100

101

- 104 2. Height between the 3rd and 25th percentiles (P3~P25),
- 3. The annual growth rate of height is less than 5 cm. 105

Exclusion Criteria 106

- 107 1. Inherited metabolic diseases: trisomy 21 syndrome, Turner syndrome,
- hypothyroidism, hyperthyroidism, deficiency, 108 growth hormone SGA,
- hypophosphatemic anti-D rickets. 109
- 2. Use of various antibiotics, antimicrobials, immunosuppressive drugs, other 110
- probiotics, prebiotics, various dietary therapies, large doses of nutrients, and other 111
- concurrent alternative therapies within the past one month. 112
- 3. Bone metabolic diseases: achondroplasia, osteogenesis imperfecta, moderate to 113
- severe nutritional rickets. 114
- 4. Chronic diarrhea, asthma. 115
- 5. Other underlying diseases (leukemia, thalassemia, aplastic anemia, etc.). 116

6. Other circumstances considered by the investigator to be inappropriate for inclusion

in the trial.

117

119

Withdrawal criteria

- 120 1. Misdiagnosis and incorrect admission.
- 2. Eligible patients who met the inclusion criteria did not take drugs after enrollment;
- 122 3. No post-treatment records.
- 4. During the trial, subjects used drugs that influenced the efficacy of the study drugs
- that were prohibited by the study.

125 Intervention

- Dose, route and duration of administration
- a. Take 40 drops of BL-11 daily (20 drops twice a day, recommended half an hour
- after breakfast and half an hour before going to bed for best results).
- b. Shake thoroughly and then drop into the mouth or add to other food to eat.
- 130 c. Continue for 3 months.
- Remark: Subjects or their guardians should properly use the study drugs under
- appropriate guidance and training. The precautions for drug use are as follows:
- a. Take care that the mouth of the bottle and dropper do not touch the skin and saliva
- during the eating process.
- b. Add oil droplets to foods or drinks at temperatures not higher than 37 °C, which
- can impair probiotic activity.
- c. If the probiotic oil drops are dropped into water or liquid food for consumption, it is
- recommended to drink within 20 minutes in order to maintain the activity of

d. Shake the product well before eating, shaking helps the probiotics to disperse more

probiotics.

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

evenly. e. Do not take it with antibiotics. If antibiotics are used, take it at least 2 hours apart. f, it is recommended to use it within 45 days after opening the lid. At the same time, subjects or their guardians should carefully fill in the patient diary card to record the patient's medication process. Data collection Height measurements: Height measurements were performed by the same, trained researchers as much as possible at the same time in the morning. Height was measured with the use of a calibrated wall height meter, and three values were measured and recorded at each visit. If the 3 measurements of height are different from each other. 0.5 cm, then the height was measured three times again until the difference between the two measurements was ≤ 0.5 cm. To measure your height, use the following procedure: Height measurements were recommended to be performed in the morning by the same trained researcher. 1. Use a calibrated height meter. 2. Subjects should not stretch before height determination. 3. The subjects had to be standing with no shoes (bare feet or socks only). 4. The subject should wear only light clothing so that the body posture of the subject can be observed.

5. Subjects had to look ahead horizontally.

6. Heel must be close together. If the subject had genu valgum (knee buckle), the 162

knees had to touch each other and the heels had to be as close to each other as

possible. 164

161

163

165

167

173

174

175

176

177

178

179

181

182

7. Heel, buttocks, shoulders and occipital bones must be in contact with the height

measuring instrument. 166

8. The mandible (chin) must be tightened upward.

168 9. The shoulders should be relaxed and the abdomen tightened to reduce lordosis

169 (curvature of the spine).

10. Lower the slide ruler or weight headrest until it is in contact with the highest part 170

of the subject's head. 171

172 11. The height measurement person read and recorded the measurement value.

12. Have the subject step away from the height meter and repeat two more times

according to the previous procedure. Repeated measurements had to differ by 0.5 cm

or less between the two measurements. If the 3 measurements of height are different

from each other. 0.5 cm, then the height measurements were repeated three times until

the difference between the two measurements was ≤ 0.5 cm.

13. Record the measurement value and measurement time.

Statistics

All the information obtained was transferred to a Microsoft Excel® 2021 table 180

where age in months, sex, height, and percentiles were recorded. GraphPad Prism 8

(San Diego, USA) was employed for statistical analysis. Data were presented as mean

± SEM, and figures were generated using the same software. The unpaired Student's t-test was utilized to assess differences. Statistical significance was established at P < 0.05.

Results

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

Study design and characteristics of participants

To evaluate the growth-promoting effect of Bifidobacterium animalis subsp. lactis BL-11 (BL-11), we enrolled 124 participates, consisting of 60 boys and 64 girls. These children ranged in age from 3 to 7 years, with the average age of 60.8 months. The height of participants ranged from 92 to 117 cm, with a mean height of 104.6 cm (Table 1). Each participant consumed 40 drops of BL-11 oiling agent daily (total live bacteria ≥ 30 billion/day) for 3 months. Heights were measured and recorded both before and after the BL-11 intervention. Finally, 124 participants with valid data were included in the height assessment. Detailed information is presented in **Supplementary Table 1.**

Table 1. Characteristics of the study population

Variables	Before intervention	After intervention
Gender, male/female (n/n)	60/64	60/64
Age, mean (months)	60.798	63.798
Height, mean (cm)	104.628	106.854

Effect of Bifidobacterium animalis subsp. lactis BL-11 on height in pediatric subjects

We analyzed height changes among the 124 participants. On average, children

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

who consumed BL-11 experienced a height increase of 2.23 cm over three months (Table 1, Figure 1A). The included children were in the preschool stage, during which the typical annual height increase is 5-6 cm. Therefore, we examined the proportion of children whose height growth rate exceeded the average expected rate of 1.5 cm over three months. A height increase greater than 1.5 cm was observed in 104 children (accounting to 83.87%), while the remaining 20 children (accounting to 16.13%) showed an increase of 1.5 cm or less (Figure 1B-C). The height percentile reflects the percentage of subjects with a certain height relative to the total number of subjects. We next analyzed height percentile before and after the BL-11 intervention. A significant increase in height percentile was observed post- intervention (Figure 1D). Of the 124 children, 108 showed an increase in height percentile, 13 showed a decrease, and 3 showed no change (Figure 1E). To further understand the impact of BL-11, we categorized the into two groups based on height percentile: P3-P10 and P10-P25. Before the BL-11 treatment, 34 children were in the P3-P10 percentile range, and 90 children were geared to P10-P25 range. After BL-11 treatment, there was a notable shift, with only 15 children remaining in the P3-P10 range and 109 children moving to the P10-P25 range (Figure 1F). These results suggested that BL-11 effectively promotes height growth in children, particularly those with shorter stature.




Figure 1. Effect of *Bifidobacterium animalis subsp. lactis* BL-11 on height in pediatric subjects. (A) The height of 124 children before and after 3-months BL-11 intervention. (B) The height change of 124 children. Red line represents a height increase greater than 1.5 cm; blue line represents a height increase less than 1.5 cm. (C) The proportions of children whose height has increased by more than 1.5 cm and less than 1.5 cm. (D) The height percentile of 124 children before and after 3-months BL-11 intervention. (E) The height percentile change of 124 children. Red line represents an increase; blue line represents a decline; gray line represents unchanged. (F) The number of children in P3-P10 and P10-P25 rages before and after 3-months BL-11 intervention. **P<0.01, ***P<0.001.

Effect of Bifidobacterium animalis subsp. lactis BL-11 on height in children by

gender

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

To determine if the growth-promoting effect of BL-11 varies by gender, we conducted a subgroup analysis of the cohort based on gender. The height tended to be increased among both male and female children after the three-month BL-11 intervention, although the increase was not statistically significant (Figure 2A). Among the 60 male participants, 50 (83.33%) experienced a height increase greater than 1.5 cm, while 10 (16.67%) showed an increase of 1.5 cm or less (Figure 2B-C). Similarly, of the 64 female participants, 54 (84.38%) had a height increase greater than 1.5 cm, and 10 (15.62%) had an increase of 1.5 cm or less (Figure 2B-C). Although the overall height increase was not statistically significant, the height percentiles showed a notable improvement in both male and female children after BL-11 treatment (Figure 2D). Among the male participants, 51 showed an increase in height percentile, 7 showed a decrease, and 2 showed no change (Figure 2E). Among the female children, 57 showed an increase in height percentile, 6 showed a decrease, and 1 showed no change (Figure 2E). At the baseline, 15 male and 19 female children were in the P3-P10 percentile range, while 45 male and 45 female children were in the P10-P25 percentile range. Post the BL-11 intervention, only 4 male and 11 female children remained in the P3-P10 range, whereas 56 male and 53 female individuals moved to the P10-P25 range (Figure 2F). Above data indicate that BL-11 effectively promotes height growth in children regardless of gender.




Figure 2. Effect of *Bifidobacterium animalis subsp. lactis* BL-11 on height in children by gender. (A) The height of male and female children before and after 3-months BL-11 intervention. (B) The height change of male and female children. Red line represents a height increase greater than 1.5 cm; blue line represents a height increase less than 1.5 cm. (C) The proportions of male and female children whose height has increased by more than 1.5 cm and less than 1.5 cm, respectively. (D) The height percentile of male and female children before and after 3-months BL-11 intervention. (E) The height percentile change of male and female children. Red line represents an increase; blue line represents a decline; gray line represents unchanged. (F) The number of male or female children in P3-P10 and P10-P25 rages before and after 3-months BL-11 intervention. *P<0.05, **P<0.01.

Effect of Bifidobacterium animalis subsp. lactis BL-11 on height in children by age

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Next, we analyzed the age distribution of our cohort, dividing it into six stages: 3 children aged 30-40 months, 24 children aged 40-50 months, 29 children aged 50-60 months, 40 children aged 60-70 months, 20 children aged 70-80 months, and 8 children aged 80-90 months. For further analysis, we divided the children into two subgroups based on 60 months as the boundary, with 56 children under 60 months old and 68 participates aged 60 months or older (Figure 3A). Overall, the height was markedly increased in both two subgroups (Figure 3B). Among the children under 60 months old, 50 individuals (89.29%) experienced a height increase greater than 1.5 cm, while 6 participants (10.71%) showed an increase of 1.5 cm or less (Figure **3C-D)**. For those aged 60 months or older, 54 individuals (79.41%) had a height growth rate greater than 1.5 cm, while 14 individuals (20.59%) presented a height growth rate less than 1.5 cm (Figure 3C,E). The height percentile also strikingly increased in both subgroups (Figure 3F). Specifically, among children under 60 months old, the percentile decreased in 6 children and increased in 49 children. Among children aged 60 months or older, the percentile decreased in 7 children and increased in 59 children (Figure 3G). At the baseline, 17 children in both age groups were in the P3-P10 percentile range, while 39 children children under 60 months old and 51 children aged 60 months 0r older were in the P10-P25 percentile range, Post the BL-11 intervention, only 8 children under 60 months old and 7 children aged 60 months or older remained in the P3-P10 range, whereas 48 children under 60 months old and 61 children aged 60 months or older moved to the P10-P25 range (Figure 3F). These data indicate that

BL-11 effectively enhances height growth in children regardless of age.




Figure 3. Effect of *Bifidobacterium animalis subsp. lactis* BL-11 on height in children by age. (A) The age distribution of 124 children. (B) The height of children aged under 60 months or over 60 months before and after 3-months BL-11 intervention. (C) The height change of children aged under 60 months or over 60 months. Red line represents a height increase greater than 1.5 cm; blue line represents a height increase less than 1.5 cm. (D) The proportions of children aged under 60 months whose height has increased by more than 1.5 cm and less than 1.5 cm. (E) The

proportions of children aged over 60 months whose height has increased by more than 1.5 cm and less than 1.5 cm. (F) The height percentile of children aged under 60 months or over 60 months before and after 3-months BL-11 intervention. (G) The height percentile change of children aged under 60 months or over 60 months. Red line represents an increase; blue line represents a decline; gray line represents unchanged. (H) The number of children aged under 60 months in P3-P10 and P10-P25 rages before and after 3-months BL-11 intervention. (I) The number of children aged over 60 months in P3-P10 and P10-P25 rages before and after 3-months BL-11 intervention. **P<0.01.

Effect of Bifidobacterium animalis subsp. lactis BL-11 on height in children within

different height ranges

Based on the above analyses, we found that BL-11 has different effects on the height of children within the P3-P10 and P10-P25 height percentiles. Therefore, we reanalyzed the population within the in these two height ranges. The height showed an increasing trend in both the P3-P10 and P10-P25 groups following the BL-11 intervention, although the increase was not statistically significant (Figure 4A). Within the P3-P10 range, 29 (85.29%) children experienced a height increase greater than 1.5 cm, while 5 (14.71%) children increased less than 1.5 cm (Figure 4B-C). Comparatively, in the P10-P25 range, 75 (83.33%) children had a height increase greater than 1.5 cm, while 15 (16.67%) children had an increase less than 1.5 cm (Figure 4B-C).

The height percentile notably increased in both the P3-P10 and P10-P25 groups following the BL-11 intervention (Figure 4D). Among children in the P3-P10 range, 30 showed an increase in height percentile, while 3 showed a decrease (Figure 4E). In the P10-P25 range, 78 children showed an increase inn height percentile, while 10 children showed a decline (Figure 4E). Overall, BL-11 effectively shifted the height range of 20 children from P3-P10 to P10-P25 (Figure 4F), displaying a superior growth-promoting effect.




Figure 4. Effect of *Bifidobacterium animalis subsp. lactis* **BL-11 on height in children within different height ranges**. (A) The height of children within the P3-P10 and P10-P25 ranges before and after 3-months BL-11 intervention. (B) The height change of children within the P3-P10 and P10-P25 ranges. Red line represents a height increase greater than 1.5 cm; blue line represents a height increase less than 1.5 cm. (C) The proportions of children within the P3-P10 and P10-P25 ranges whose

height has increased by more than 1.5 cm and less than 1.5 cm, respectively. (D) The height percentile of children within the P3-P10 and P10-P25 ranges before and after 3-months BL-11 intervention. (E) The height percentile change of children within the P3-P10 and P10-P25 ranges. Red line represents an increase; blue line represents a decline; gray line represents unchanged. (F) The number of children in P3-P10 and P10-P25 rages before and after 3-months BL-11 intervention. ***P<0.001.

Discussions

Early childhood is a period of rapid development in metabolism, endocrine, immunity, and neural development, all of which strongly affect the growth and development of children. Therefore, it is necessary to explore strategies to promote the growth of children with short stature. The present cohort assessed the growth-promoting effect of *Bifidobacterium animalis subsp. lactis* BL-11 among 124 children aged 3-7 years old with height ranging from 92 to 117. Positively, three-months intervention with *Bifidobacterium animalis subsp. lactis* BL-11 significantly promoted height growth in these children, with no difference observed based on gender or age. To a certain extent, these clinical trial data demonstrate that treatment with specific probiotics strain can favorably impact children's growth and development. This finding is likely to attract the attention of pediatrician and parents concerned about short stature in children.

The chief indicators of short stature in children are their height and weight. Growth disorders, such as short stature or growth failure, are often markers of

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

underlying conditions like nutritional deficits, abnormal hormone metabolism, diarrhoeal disease or cardiovascular disease [16]. Currently, measures to promote children's growth primarily include calcium agent supplementation and growth hormone-like drugs. While these treatments are effective for many individuals, the daily injections can be painful and and intolerable, particularly for children, leading to the non-adherence and reduced treatment outcomes [17]. Obviously, it is meaningful to explore complementary or alternative therapies that are both effective and safe. The gut microbiota, which colonizes and stabilizes within the human intestine during the childhood, plays a crucial role in growth and development. Compelling evidences have confirmed that those gut bacteria contribute to lifelong and intergenerational deficits in growth and development among children [18]. Probiotic strains of Bifidobacterium are increasingly being used in pharmaceuticals and functional foods [19]. Bifidobacterium animalis subsp. lactis is one of the probiotics that supports the intestinal health, metabolic balance and growth performance [20-22], indicating its potential as a candidate for height management. Consistent with the speculation, our study found that Bifidobacterium animalis subsp. lactis BL-11 notably enhanced the height of children, implying that early probiotic supplementation might prevent the occurrence of short status. Generally, children's height is determined by their longitudinal growth index, which is influenced by hereditary factors, nutrition, sleep, sports, hormone level, environment, habits, and race [23]. Several Bifidobacterium strains, such as Bifidobacterium longum and Bifidobacterium pseudocatenulatum CECT 7765, are

demonstrated to increase serum osteocalcin and minerals concentration, along with decrease serum C-terminal telopeptide and parathormone, thereby favor a femur growth [24,25]. Our present study displayed growth-promoting effect of another Bifidobacterium strain — Bifidobacterium animalis subsp. lactis BL-11. While the study was promising, it failed to provide mechanisms since mechanistic studies were not performed. Ding et al. revealed that strain of Bifidobacterium longum subsp. infantis CCFM1269 can modulate gut microbiota and metabolites, stimulate GH/IGF-1 axis in growing mice [26]. We, therefore, cautiously speculate that the growth-promoting mechanism of Bifidobacterium animalis subsp. lactis BL-11 is related with the GH/IGF-1 pathway. Additionally, it is reported that Bifidobacterium longum can modulate Treg-Th17 cell balance, elevate anti-osteoclastogenic cytokines IFN-γ and IL-10 and decrease osteoclastogenic-cytokines IL-6, IL-17, and TNF-α [27]. Hence, the immunomodulatory potential of *Bifidobacterium animalis subsp.* lactis BL-11 may also be conducive to its growth-promoting effect. A further study should elucidate the mechanisms of how Bifidobacterium animalis subsp. lactis BL-11 promote bone growth, thus promote effective and efficient probiotic products development.

Conclusions

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

Collectively, the foregoing data demonstrated that *Bifidobacterium animalis* subsp. lactis BL-11 intervention is in favor of the child's growth and development. This cohort study proposes that early supplementary with *Bifidobacterium animalis* subsp. lactis BL-11 could help prevent short stature in children. These findings

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

Reference

provide pediatricians with a potential strategy to effectively and safely promote children's growth. **Author Approval** All authors have seen and approved the manuscript. **Declaration of competing interest** The authors declare that they have no known financial interests or personal relationships that might influence the work reported in this paper. **Acknowledgments** None **CRediT** authorship contribution statement Q.W.: Methodology, Formal Analysis, Visualization, Writing-Review & Editing; Y.Y.: Methodology, Formal Analysis, Visualization, Writing-Review & Editing; Y.X.: Visualization, Formal Analysis, Writing-original draft; Z.L.: Visualization, Formal Analysis, Writing-original draft; M.L.: Methodology, Writing-Review & Editing; Y.Y.: Methodology, Writing-Review & Editing; N.W.: Methodology, Investigation; J.L.: Methodology, Investigation; X.L.: Visualization; C.X.: Visualization; D.L.: Conceptualization, Data Curation, Formal Analysis, Visualization, Writing-Review & Editing; C.W.: Conceptualization, Data Curation, Formal Analysis, Visualization, Writing-Review & Editing. Data availability All data are available from the corresponding authors upon reasonable request.

423	[1]	Dewey KG, Begum K. Long-term consequences of stunting in early life. Maternal & Child
424		Nutrition 2011; 7: 5-18.
425	[2]	Black MM, Tofail F, Hodges EA, Bann CM, Hamadani JD, Aktar S, et al. Rethinking
426		Responsive Feeding: Insights from Bangladesh. Nutrients 2022; 14:
427	[3]	Ad R, Gf H. Etiologies and early diagnosis of short stature and growth failure in children and
428		adolescents. J Pediatr. 2014; 164: S1-14.e6.
429	[4]	S K, K K, M L, A K, T L, C R, et al. The association between the body height and
430		cardiovascular diseases: a retrospective analysis of 657,310 outpatients in Germany. Eur J
431		Med Res. 2022; 27: 240.
432	[5]	Y J, T H, Yh D. The relationship of the waist to stature ration with type 2 diabetes mellitus.
433		Chin J Diabetes 2010; 18: 526-8.
434	[6]	Ta P, Nk O, P K, Pj K. Short stature is associated with coronary heart disease: a systematic
435		review of the literature and a meta-analysis. Eur Heart J. 2010; 31: 1802-9.
436	[7]	S S, Id O, Mc C, A E, Id O, C H, et al. The International Scientific Association of Probiotics
437		and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat
438		Rev Gastroenterol Hepatol 2021; 18: 649-67.
439	[8]	Xu W, Yu J, Yang Y, Li Z, Zhang Y, Zhang F, et al. Strain-level screening of human gut
440		microbes identifies Blautia producta as a new anti-hyperlipidemic probiotic. Gut Microbes
441		2023; 15: 2228045.
442	[9]	Yang YN, Wang QC, Xu W, Yu J, Zhang H, Wu C. The berberine-enriched gut commensal
443		Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver
444		LDLR expression. Biomed Pharmacother 2022; 155: 113749.

445	[10]	Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sanchez B, Margolles A.
446		Bifidobacteria and Their Health-Promoting Effects. Microbiol Spectr 2017; 5:
447	[11]	Chen K, Zhang G, Xie H, You L, Li H, Zhang Y, et al. Efficacy of Bifidobacterium animalis
448		subsp. lactis, BB-12((R)) on infant colic - a randomised, double-blinded, placebo-controlled
449		study. Benef Microbes 2021; 12: 531-40.
450	[12]	Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium
451		lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel
452		Syndrome: Randomized Controlled Trial. Nutrients 2020; 12:
453	[13]	Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium
454		lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA
455		in preterm infants. Pediatr Res 2008; 64: 418-22.
456	[14]	Steenhout PG, Rochat F, Hager C. The effect of Bifidobacterium lactis on the growth of
457		infants: a pooled analysis of randomized controlled studies. Annals of Nutrition and
458		Metabolism 2009; 55: 334-40.
459	[15]	Xj K, G W, R T, S L, K L, C C, et al. The Effects of Probiotic Supplementation on
460		Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi
461		Syndrome: A Randomized Double-Blinded Placebo-Controlled Trial. Front Nutr 2021; 8:
462	[16]	Teran E, Chesner J, Rapaport R. Growth and growth hormone: An overview. Growth Horm
463		IGF Res 2016; 28: 3-5.
464	[17]	Yuen KCJ, Miller BS, Boguszewski CL, Hoffman AR. Usefulness and Potential Pitfalls of
465		Long-Acting Growth Hormone Analogs. Front Endocrinol (Lausanne) 2021; 12: 637209.

466	[18]	Robertson RC, Manges AR, Finlay BB, Prendergast AJ. The Human Microbiome and Child
467		Growth – First 1000 Days and Beyond. Trends in Microbiology 2019; 27: 131-47.
468	[19]	Jamalifar H, Bigdeli B, Nowroozi J, Zolfaghari HS, Fazeli MR. Selection for autochthonous
469		bifidobacteial isolates adapted to simulated gastrointestinal fluid. Daru 2010; 18: 57-66.
470	[20]	Cheng J, Laitila A, Ouwehand AC. Bifidobacterium animalis subsp. lactis HN019 Effects on
471		Gut Health: A Review. Front Nutr 2021; 8: 790561.
472	[21]	Uusitupa HM, Rasinkangas P, Lehtinen MJ, Makela SM, Airaksinen K, Anglenius H, et al.
473		Bifidobacterium animalis subsp. lactis 420 for Metabolic Health: Review of the Research.
474		Nutrients 2020; 12:
475	[22]	Abdel-Moneim AE, Elbaz AM, Khidr RE, Badri FB. Effect of in Ovo Inoculation of
476		Bifidobacterium spp. on Growth Performance, Thyroid Activity, Ileum Histomorphometry,
477		and Microbial Enumeration of Broilers. Probiotics Antimicrob Proteins 2020; 12: 873-82.
478	[23]	Li YY, Chen Y, Xu X, Tan BY, Liu YB, Peng X, et al. Analysis of Prevalence, Influencing
479		Factors, and Countermeasures of Short Stature in Children and Adolescents Aged 6~ 14 in
480		Furong District, Changsha City, in 2020. Evid Based Complement Alternat Med. 2021; 2021:
481		3933854.
482	[24]	Fc R, As C, Vc R, Sa F, Ea F, Tt DO, et al. Yacon flour and Bifidobacterium longum modulate
483		bone health in rats. J Med Food. 2012; 15: 664-70.
484	[25]	Fernández-Murga ML, Olivares M, Sanz Y. Bifidobacterium pseudocatenulatum CECT 7765
485		reverses the adverse effects of diet-induced obesity through the gut-bone axis. Bone 2020;
196		141.

141:

487	[26]	Ding M, Li B, Chen H, Liang D, Ross RP, Stanton C, et al. Human breastmilk-derived
488		Bifidobacterium longum subsp. infantis CCFM1269 regulates bone formation by the GH/IGF
489		axis through PI3K/AKT pathway. Gut Microbes 2023; 16:
490	[27]	Sapra L, Shokeen N, Porwal K, Saini C, Bhardwaj A, Mathew M, et al. Bifidobacterium
491		longum Ameliorates Ovariectomy-Induced Bone Loss via Enhancing Anti-Osteoclastogenic
492		and Immunomodulatory Potential of Regulatory B Cells (Bregs). Frontiers in Immunology
493		2022; 13:
494		
495		

